Krabbe's disease (KD) is caused by mutations in the lysosomal enzyme galactocerebrosidase and is associated with psychosine toxicity. The sphingosine 1-phosphate receptor (S1PR) agonist fingolimod (FTY720) attenuates psychosine-induced cell death of human astrocytes, demyelination in cerebellar slices, as well as demyelination in the central nervous system of twitcher mice. Psychosine also accumulates in the peripheral nervous system in twitcher mice; however, effects of fingolimod on this peripheral myelin have not been examined. The aim of this study was to investigate the effects of fingolimod administration on peripheral and central markers of myelination. Here, we report that fingolimod administration (1 mg/kg/day) from postnatal day 5 (PND) onwards did not alter peripheral demyelination in the sciatic nerve of twitcher mice, despite significantly reducing myelin debris, glial reactivity, and neuronal damage in the cerebellum. We also find fingolimod administration improves twitching and mobility scores in twitcher mice. Importantly, we find that fingolimod significantly increases the lifespan of twitcher mice by approximately 5 days. These findings suggest differential effects of fingolimod on peripheral and central neuropathy in twitcher mice, which may explain its modest efficacy on behavior and lifespan.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10967782 | PMC |
| http://dx.doi.org/10.3390/biomedicines12030594 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A lipid nanoparticle-based oligodendrocyte-specific mRNA therapy.
Mol Ther Nucleic Acids
December 2024
Department of Therapeutics for Multiple System Atrophy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Article Synopsis
- The study highlights the challenge of delivering mRNA therapies effectively into oligodendrocytes, a type of brain cell, as traditional viral vectors aren't effective.
- Researchers utilized LUNAR lipid nanoparticles to achieve high efficiency and specificity in delivering mRNA to these cells, leveraging low-density lipoprotein receptors with the help of apoprotein E.
- A single dose of LUNAR-human galactosylceramidase mRNA significantly improved the health and survival of twitcher mice, a model for Krabbe disease, showcasing the potential of this method for treating neurological disorders related to oligodendrocytes.
Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain-Study in a Mouse Model of the Disease.
Int J Mol Sci
June 2024
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Lipid mediators from fatty acid oxidation have been shown to be associated with the severity of Krabbe disease (KD), a disorder linked to mutations in the galactosylceramidase () gene. This study aims to investigate the effects of n-3 polyunsaturated fatty acid (PUFA) supplementation on KD traits and fatty acid metabolism using Twitcher (Tw) animals as a natural model for KD. Wild-type (Wt), heterozygous (Ht), and affected Tw animals were treated orally with 36 mg n-3 PUFAs/kg body weight/day from 10 to 35 days of life.
View Article and Find Full Text PDFPromyelinating drugs ameliorate oligodendrocyte pathologies in a mouse model of Krabbe disease.
Mol Genet Metab
July 2024
Department of Cellular Pathology, Institute for Developmental Research, Aichi Developmental Disability Center, 713-8 Kamiya-cho, Kasugai, Aichi 480-0392, Japan. Electronic address:
Krabbe disease (KD) is a rare inherited demyelinating disorder caused by a deficiency in the lysosomal enzyme galactosylceramide (GalCer) β-galactosidase. Most patients with KD exhibit fatal cerebral demyelination with apoptotic oligodendrocyte (OL) death and die before the age of 2-4 years. We have previously reported that primary OLs isolated from the brains of twitcher (twi) mice, an authentic mouse model of KD, have cell-autonomous developmental defects and undergo apoptotic death accompanied by abnormal accumulation of psychosine, an endogenous cytotoxic lyso-derivative of GalCer.
View Article and Find Full Text PDFImpact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos.
Comput Struct Biotechnol J
December 2024
Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Krabbe disease is a sphingolipidosis characterized by the genetic deficiency of the acid hydrolase β-galactosylceramidase (GALC). Most of the studies concerning the biological role of GALC performed on Krabbe patients and -deficient mice (an authentic animal model of the disease) indicate that the pathogenesis of this disorder is the consequence of the accumulation of the neurotoxic GALC substrate β-galactosylsphingosine (psychosine), ignoring the possibility that this enzyme may exert a wider biological impact. Indeed, limited information is available about the effect of GALC downregulation on the cell lipidome in adult and developing organisms.
View Article and Find Full Text PDFThe Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease.
Mol Neurobiol
November 2024
Drug Development, Department of Physiology, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.
Krabbe disease (KD) is a rare demyelinating disorder characterized by demyelination caused by mutations in the GALC gene, resulting in toxic accumulation of psychosine. Psychosine has been identified as detrimental to oligodendrocytes, leading to demyelination through diverse hypothesized pathways. Reducing demyelination is essential to maintain neurological function in KD; however, therapeutic interventions are currently limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!